You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

E200K mutation

Showing 1 - 25 of 8,857
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stratification of Overlap Syndrome Phenotype in E1784K Mutation

Recruiting
  • Long QT Syndrome
  • +3 more
    • Saint-Pierre, France, Réunion
      CHU de La Réunion
    Oct 19, 2022

    Osteoarthrosis Trial in Seoul (E1K 1,200 ?/joint, E1K 2,400 ?/joint, )

    Recruiting
    • Osteoarthrosis
    • E1K 1,200 ㎍/joint
    • +2 more
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Jan 15, 2023

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)

    Recruiting
    • Creutzfeldt-Jakob Disease (CJD)
      • Tel Aviv, Israel
        Cognitive Neurology Unit
      Feb 27, 2023

      Medium-chain Acyl-CoA Dehydrogenase Deficiency Trial in Pittsburgh (Sodium phenylbutyrate)

      Recruiting
      • Medium-chain Acyl-CoA Dehydrogenase Deficiency
      • Sodium phenylbutyrate
      • Pittsburgh, Pennsylvania
        UPMC Children's Hospital of Pittsburgh
      Oct 4, 2023

      Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

      Active, not recruiting
      • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 9, 2022

      EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)

      Recruiting
      • EGFR NP_005219.2:p.S492R
      • +7 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

      Completed
      • Metastatic Melanoma
      • Palliative radiotherapy
      • Dabrafenib and trametinib (combination)
      • Darlinghurst, New South Wales, Australia
      • +2 more
      Apr 6, 2022

      BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

      Recruiting
      • BRAF NP_004324.2:p.V600E
      • +2 more
      • Duarte, California
      • +1 more
      Jan 19, 2023

      BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

      Active, not recruiting
      • BRAF V600E Mutation Present
      • +9 more
      • Boston, Massachusetts
      • +1 more
      Jun 28, 2022

      Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

      Recruiting
      • Melanoma
      • Siena, Toscana, Italy
      • +11 more
      Jun 23, 2023

      Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor Trial (drug, procedure, biological)

      Not yet recruiting
      • Advanced Malignant Solid Neoplasm
      • Locally Advanced Malignant Solid Neoplasm
      • (no location specified)
      Dec 2, 2022

      BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

      Terminated
      • BRAF V600E Mutation Present
      • +7 more
      • Boston, Massachusetts
      • +1 more
      Mar 9, 2022

      Advanced NSCLC, Metastatic NSCLC Trial in Worldwide (MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab)

      Recruiting
      • Advanced Non-Small Cell Lung Cancer
      • Metastatic Non-Small Cell Lung Cancer
      • MRTX849 Monotherapy
      • +2 more
      • Prescott Valley, Arizona
      • +134 more
      Jan 25, 2023

      Parkinson's Disease Trial in Worldwide (venglustat GZ/SAR402671, Placebo)

      Terminated
      Has Results
      • Parkinson's Disease
      • venglustat GZ/SAR402671
      • Placebo
      • Scottsdale, Arizona
      • +51 more
      May 3, 2022

      Locally Advanced or Metastatic Breast Cancer Trial in Canada, Israel, United States (Lasofoxifene, Fulvestrant)

      Active, not recruiting
      • Locally Advanced or Metastatic Breast Cancer
      • Phoenix, Arizona
      • +50 more
      Oct 24, 2022

      Non-squamous NSCLC Trial (biological, drug, dietary supplement)

      Not yet recruiting
      • Non-squamous NSCLC
      • Pembrolizumab
      • +7 more
      • (no location specified)
      Feb 20, 2023

      Hidradenitis Suppurativa Trial in Canada, Poland, United States (Ruxolitinib cream, Vehicle cream)

      Recruiting
      • Hidradenitis Suppurativa
      • Ruxolitinib cream
      • Vehicle cream
      • Phoenix, Arizona
      • +26 more
      Dec 13, 2022

      ER-Positive HER2-Negative Breast Cancer Trial in Worldwide (AZD9833, AZD9833 Placebo, Anastrozole)

      Recruiting
      • ER-Positive HER2-Negative Breast Cancer
      • Phoenix, Arizona
      • +215 more
      Aug 4, 2022

      Cystinosis, Primary Hyperoxaluria Trial in Hanover (Diagnostic test)

      Recruiting
      • Cystinosis
      • Primary Hyperoxaluria
      • Diagnostic test
      • Hanover, Lower Saxony, Germany
        Screening Laboratory Hanover
      Apr 24, 2023

      KCNJ11-related Intermediate Developmental Delay, Epilepsy and

      Recruiting
      • Neurodevelopmental Disorders
      • +5 more
      • Chicago, Illinois
      • +3 more
      Feb 20, 2023

      Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer Trial in Worldwide (Speiser-catheter for uterine and tubal lavage)

      Completed
      • Ovarian Epithelial Cancer
      • +2 more
      • Speiser-catheter for uterine and tubal lavage
      • Graz, Austria
      • +8 more
      Sep 1, 2022

      NSCLC, Colorectal Cancer, Advanced Solid Tumors Trial in Worldwide (GDC-6036, Atezolizumab, Cetuximab)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Duarte, California
      • +68 more
      Jan 10, 2023

      Melanoma Trial in New York (Dabrafenib)

      Completed
      Has Results
      • Melanoma
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      May 8, 2020

      Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination

      Not yet recruiting
      • Elderly AML Patients
      • +4 more
      • Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
      • Active Comparator: Standard dose of Venetoclax + Azacitidine
      • Kunming, Yunnan, China
        The Second Affiliated Hospital of Kunming Medical University.
      Oct 3, 2023